Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards

Research output: Contribution to journalReview articleResearchpeer review

Authors

  • Jörg Ruof
  • Jan L. Hülsemann
  • Thomas Mittendorf
  • Silke Handelmann
  • Rick Aultman
  • J. Matthias Von Der Schulenburg
  • Henning Zeidler
  • Sonja Merkesdal

External Research Organisations

  • Hannover Medical School (MHH)
View graph of relations

Details

Original languageEnglish
Pages (from-to)64-69
Number of pages6
JournalEuropean Journal of Health Economics
Volume5
Issue number1
Early online date24 Sept 2003
Publication statusPublished - Feb 2004

Abstract

Accurate estimation of medical care costs raises a host of challenging issues. We examined whether pure administrative claims data without clinical validation of diagnosis allow reasonable estimation of disease-related costs in rheumatoid arthritis (RA). Three patient groups were examined: patients with clinically confirmed RA (group A, n=338), patients with likely RA (administrative claims data reported the diagnosis of RA and patients were treated with disease modifying antirheumatic drugs, DMARDs; group B, n=303), and patients with possible RA (same as group B but patients had no DMARD treatment; group C, n=685). The payer's perspective was taken for this analysis. Only direct costs were included in the analysis. Cost data and data for several covariates were obtained from a major German statutory health insurance plan, the AOK Niedersachsen. A patient-per-patient microcosting approach was performed. A repeated measures, fixed effect model was applied to examine differences between the three study groups. Mean±SEM annual RA-related direct costs were € 2,017±183 per patient-year in group A, € 1763±192 in group B, and € 805±58 in group C. Outpatient (inpatient) costs were € 1636 (328) in group A, € 1344 (340) in group B, and € 546 (136) in group C. DMARD costs were by far the single most important cost driver in groups A and B. The difference in total RA-related direct cost between groups A and B was not significant whereas the differences between groups A and C (group B and C respectively), were significant. Pure administrative claims data allowed for an accurate estimate of disease-related costs-in RA patients that received DMARD therapy. However, the high number of patients for whom administrative claims data listed the diagnosis RA, but no DMARD treatment was given poses a challenge for further research.

Keywords

    Cost of illness, Health economics, Rheumatoid arthritis

ASJC Scopus subject areas

Sustainable Development Goals

Cite this

Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards. / Ruof, Jörg; Hülsemann, Jan L.; Mittendorf, Thomas et al.
In: European Journal of Health Economics, Vol. 5, No. 1, 02.2004, p. 64-69.

Research output: Contribution to journalReview articleResearchpeer review

Ruof, J, Hülsemann, JL, Mittendorf, T, Handelmann, S, Aultman, R, Von Der Schulenburg, JM, Zeidler, H & Merkesdal, S 2004, 'Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards', European Journal of Health Economics, vol. 5, no. 1, pp. 64-69. https://doi.org/10.1007/s10198-003-0203-4
Ruof, J., Hülsemann, J. L., Mittendorf, T., Handelmann, S., Aultman, R., Von Der Schulenburg, J. M., Zeidler, H., & Merkesdal, S. (2004). Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards. European Journal of Health Economics, 5(1), 64-69. https://doi.org/10.1007/s10198-003-0203-4
Ruof J, Hülsemann JL, Mittendorf T, Handelmann S, Aultman R, Von Der Schulenburg JM et al. Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards. European Journal of Health Economics. 2004 Feb;5(1):64-69. Epub 2003 Sept 24. doi: 10.1007/s10198-003-0203-4
Download
@article{098b8987e68b4dada76718d2d0563ee9,
title = "Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards",
abstract = "Accurate estimation of medical care costs raises a host of challenging issues. We examined whether pure administrative claims data without clinical validation of diagnosis allow reasonable estimation of disease-related costs in rheumatoid arthritis (RA). Three patient groups were examined: patients with clinically confirmed RA (group A, n=338), patients with likely RA (administrative claims data reported the diagnosis of RA and patients were treated with disease modifying antirheumatic drugs, DMARDs; group B, n=303), and patients with possible RA (same as group B but patients had no DMARD treatment; group C, n=685). The payer's perspective was taken for this analysis. Only direct costs were included in the analysis. Cost data and data for several covariates were obtained from a major German statutory health insurance plan, the AOK Niedersachsen. A patient-per-patient microcosting approach was performed. A repeated measures, fixed effect model was applied to examine differences between the three study groups. Mean±SEM annual RA-related direct costs were € 2,017±183 per patient-year in group A, € 1763±192 in group B, and € 805±58 in group C. Outpatient (inpatient) costs were € 1636 (328) in group A, € 1344 (340) in group B, and € 546 (136) in group C. DMARD costs were by far the single most important cost driver in groups A and B. The difference in total RA-related direct cost between groups A and B was not significant whereas the differences between groups A and C (group B and C respectively), were significant. Pure administrative claims data allowed for an accurate estimate of disease-related costs-in RA patients that received DMARD therapy. However, the high number of patients for whom administrative claims data listed the diagnosis RA, but no DMARD treatment was given poses a challenge for further research.",
keywords = "Cost of illness, Health economics, Rheumatoid arthritis",
author = "J{\"o}rg Ruof and H{\"u}lsemann, {Jan L.} and Thomas Mittendorf and Silke Handelmann and Rick Aultman and {Von Der Schulenburg}, {J. Matthias} and Henning Zeidler and Sonja Merkesdal",
year = "2004",
month = feb,
doi = "10.1007/s10198-003-0203-4",
language = "English",
volume = "5",
pages = "64--69",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer Verlag",
number = "1",

}

Download

TY - JOUR

T1 - Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards

AU - Ruof, Jörg

AU - Hülsemann, Jan L.

AU - Mittendorf, Thomas

AU - Handelmann, Silke

AU - Aultman, Rick

AU - Von Der Schulenburg, J. Matthias

AU - Zeidler, Henning

AU - Merkesdal, Sonja

PY - 2004/2

Y1 - 2004/2

N2 - Accurate estimation of medical care costs raises a host of challenging issues. We examined whether pure administrative claims data without clinical validation of diagnosis allow reasonable estimation of disease-related costs in rheumatoid arthritis (RA). Three patient groups were examined: patients with clinically confirmed RA (group A, n=338), patients with likely RA (administrative claims data reported the diagnosis of RA and patients were treated with disease modifying antirheumatic drugs, DMARDs; group B, n=303), and patients with possible RA (same as group B but patients had no DMARD treatment; group C, n=685). The payer's perspective was taken for this analysis. Only direct costs were included in the analysis. Cost data and data for several covariates were obtained from a major German statutory health insurance plan, the AOK Niedersachsen. A patient-per-patient microcosting approach was performed. A repeated measures, fixed effect model was applied to examine differences between the three study groups. Mean±SEM annual RA-related direct costs were € 2,017±183 per patient-year in group A, € 1763±192 in group B, and € 805±58 in group C. Outpatient (inpatient) costs were € 1636 (328) in group A, € 1344 (340) in group B, and € 546 (136) in group C. DMARD costs were by far the single most important cost driver in groups A and B. The difference in total RA-related direct cost between groups A and B was not significant whereas the differences between groups A and C (group B and C respectively), were significant. Pure administrative claims data allowed for an accurate estimate of disease-related costs-in RA patients that received DMARD therapy. However, the high number of patients for whom administrative claims data listed the diagnosis RA, but no DMARD treatment was given poses a challenge for further research.

AB - Accurate estimation of medical care costs raises a host of challenging issues. We examined whether pure administrative claims data without clinical validation of diagnosis allow reasonable estimation of disease-related costs in rheumatoid arthritis (RA). Three patient groups were examined: patients with clinically confirmed RA (group A, n=338), patients with likely RA (administrative claims data reported the diagnosis of RA and patients were treated with disease modifying antirheumatic drugs, DMARDs; group B, n=303), and patients with possible RA (same as group B but patients had no DMARD treatment; group C, n=685). The payer's perspective was taken for this analysis. Only direct costs were included in the analysis. Cost data and data for several covariates were obtained from a major German statutory health insurance plan, the AOK Niedersachsen. A patient-per-patient microcosting approach was performed. A repeated measures, fixed effect model was applied to examine differences between the three study groups. Mean±SEM annual RA-related direct costs were € 2,017±183 per patient-year in group A, € 1763±192 in group B, and € 805±58 in group C. Outpatient (inpatient) costs were € 1636 (328) in group A, € 1344 (340) in group B, and € 546 (136) in group C. DMARD costs were by far the single most important cost driver in groups A and B. The difference in total RA-related direct cost between groups A and B was not significant whereas the differences between groups A and C (group B and C respectively), were significant. Pure administrative claims data allowed for an accurate estimate of disease-related costs-in RA patients that received DMARD therapy. However, the high number of patients for whom administrative claims data listed the diagnosis RA, but no DMARD treatment was given poses a challenge for further research.

KW - Cost of illness

KW - Health economics

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=1542284168&partnerID=8YFLogxK

U2 - 10.1007/s10198-003-0203-4

DO - 10.1007/s10198-003-0203-4

M3 - Review article

C2 - 15452767

AN - SCOPUS:1542284168

VL - 5

SP - 64

EP - 69

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

IS - 1

ER -